Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma

C. Porta, M. De Amici, S. Quaglini, C. Paglino, F. Tagliani, A. Boncimino, R. Moratti, G. R. Corazza

Research output: Contribution to journalArticle

102 Citations (Scopus)

Abstract

Background: A large amount of evidence suggests a possible role of interleukin-6 (IL-6) in the pathogenesis of hepatocellular carcinoma (HCC). Patients and methods: We studied both IL-6 and A1FP in patients with HCC, non-neoplastic liver disease or in healthy controls. Results: IL-6 titers were four-fold higher in cancer than in cirrhotic patients and 25-fold higher than in healthy controls. As for alpha1-fetoprotein (A1FP) titers, the highest levels were observed in cancer patients. Receiver operating characteristic (ROC) curves analysis demonstrated that IL-6 is significantly more discriminant than A1FP, with 'optimal' cut-off values of 7.9 pg/ml (sensitivity = 0.83, specificity = 0.83, efficiency = 0.83). The ROC curves used to distinguish HCC from cirrhotic patients only, showed higher discriminant power of IL-6 versus A1FP titers, with a new cut-off value of 12 pg/ml (sensitivity = 0.73, specificity = 0.87, efficiency = 0.8). Discriminant analysis on HCC and non-HCC subjects yielded sensitivity, specificity and efficiency rates of 77%, 93% and 88%, respectively. The overall efficiency of the two tests combined was 82%. Conclusions: IL-6 could be considered a promising tumor marker forHCC. In particular, the diagnostic value of the test is significantly increased when combined with A1FP.

Original languageEnglish
Pages (from-to)353-358
Number of pages6
JournalAnnals of Oncology
Volume19
Issue number2
DOIs
Publication statusPublished - Feb 2008

Fingerprint

Fetal Proteins
Tumor Biomarkers
Hepatocellular Carcinoma
Interleukin-6
Sensitivity and Specificity
ROC Curve
Discriminant Analysis
Routine Diagnostic Tests
Liver Diseases
Neoplasms
Carcinoma

Keywords

  • AFP
  • Cirrhosis
  • HCC
  • IL-6
  • Tumor markers

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma. / Porta, C.; De Amici, M.; Quaglini, S.; Paglino, C.; Tagliani, F.; Boncimino, A.; Moratti, R.; Corazza, G. R.

In: Annals of Oncology, Vol. 19, No. 2, 02.2008, p. 353-358.

Research output: Contribution to journalArticle

Porta, C. ; De Amici, M. ; Quaglini, S. ; Paglino, C. ; Tagliani, F. ; Boncimino, A. ; Moratti, R. ; Corazza, G. R. / Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma. In: Annals of Oncology. 2008 ; Vol. 19, No. 2. pp. 353-358.
@article{470725e61170405cad3b36e31d93921e,
title = "Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma",
abstract = "Background: A large amount of evidence suggests a possible role of interleukin-6 (IL-6) in the pathogenesis of hepatocellular carcinoma (HCC). Patients and methods: We studied both IL-6 and A1FP in patients with HCC, non-neoplastic liver disease or in healthy controls. Results: IL-6 titers were four-fold higher in cancer than in cirrhotic patients and 25-fold higher than in healthy controls. As for alpha1-fetoprotein (A1FP) titers, the highest levels were observed in cancer patients. Receiver operating characteristic (ROC) curves analysis demonstrated that IL-6 is significantly more discriminant than A1FP, with 'optimal' cut-off values of 7.9 pg/ml (sensitivity = 0.83, specificity = 0.83, efficiency = 0.83). The ROC curves used to distinguish HCC from cirrhotic patients only, showed higher discriminant power of IL-6 versus A1FP titers, with a new cut-off value of 12 pg/ml (sensitivity = 0.73, specificity = 0.87, efficiency = 0.8). Discriminant analysis on HCC and non-HCC subjects yielded sensitivity, specificity and efficiency rates of 77{\%}, 93{\%} and 88{\%}, respectively. The overall efficiency of the two tests combined was 82{\%}. Conclusions: IL-6 could be considered a promising tumor marker forHCC. In particular, the diagnostic value of the test is significantly increased when combined with A1FP.",
keywords = "AFP, Cirrhosis, HCC, IL-6, Tumor markers",
author = "C. Porta and {De Amici}, M. and S. Quaglini and C. Paglino and F. Tagliani and A. Boncimino and R. Moratti and Corazza, {G. R.}",
year = "2008",
month = "2",
doi = "10.1093/annonc/mdm448",
language = "English",
volume = "19",
pages = "353--358",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "2",

}

TY - JOUR

T1 - Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma

AU - Porta, C.

AU - De Amici, M.

AU - Quaglini, S.

AU - Paglino, C.

AU - Tagliani, F.

AU - Boncimino, A.

AU - Moratti, R.

AU - Corazza, G. R.

PY - 2008/2

Y1 - 2008/2

N2 - Background: A large amount of evidence suggests a possible role of interleukin-6 (IL-6) in the pathogenesis of hepatocellular carcinoma (HCC). Patients and methods: We studied both IL-6 and A1FP in patients with HCC, non-neoplastic liver disease or in healthy controls. Results: IL-6 titers were four-fold higher in cancer than in cirrhotic patients and 25-fold higher than in healthy controls. As for alpha1-fetoprotein (A1FP) titers, the highest levels were observed in cancer patients. Receiver operating characteristic (ROC) curves analysis demonstrated that IL-6 is significantly more discriminant than A1FP, with 'optimal' cut-off values of 7.9 pg/ml (sensitivity = 0.83, specificity = 0.83, efficiency = 0.83). The ROC curves used to distinguish HCC from cirrhotic patients only, showed higher discriminant power of IL-6 versus A1FP titers, with a new cut-off value of 12 pg/ml (sensitivity = 0.73, specificity = 0.87, efficiency = 0.8). Discriminant analysis on HCC and non-HCC subjects yielded sensitivity, specificity and efficiency rates of 77%, 93% and 88%, respectively. The overall efficiency of the two tests combined was 82%. Conclusions: IL-6 could be considered a promising tumor marker forHCC. In particular, the diagnostic value of the test is significantly increased when combined with A1FP.

AB - Background: A large amount of evidence suggests a possible role of interleukin-6 (IL-6) in the pathogenesis of hepatocellular carcinoma (HCC). Patients and methods: We studied both IL-6 and A1FP in patients with HCC, non-neoplastic liver disease or in healthy controls. Results: IL-6 titers were four-fold higher in cancer than in cirrhotic patients and 25-fold higher than in healthy controls. As for alpha1-fetoprotein (A1FP) titers, the highest levels were observed in cancer patients. Receiver operating characteristic (ROC) curves analysis demonstrated that IL-6 is significantly more discriminant than A1FP, with 'optimal' cut-off values of 7.9 pg/ml (sensitivity = 0.83, specificity = 0.83, efficiency = 0.83). The ROC curves used to distinguish HCC from cirrhotic patients only, showed higher discriminant power of IL-6 versus A1FP titers, with a new cut-off value of 12 pg/ml (sensitivity = 0.73, specificity = 0.87, efficiency = 0.8). Discriminant analysis on HCC and non-HCC subjects yielded sensitivity, specificity and efficiency rates of 77%, 93% and 88%, respectively. The overall efficiency of the two tests combined was 82%. Conclusions: IL-6 could be considered a promising tumor marker forHCC. In particular, the diagnostic value of the test is significantly increased when combined with A1FP.

KW - AFP

KW - Cirrhosis

KW - HCC

KW - IL-6

KW - Tumor markers

UR - http://www.scopus.com/inward/record.url?scp=38849106118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38849106118&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdm448

DO - 10.1093/annonc/mdm448

M3 - Article

C2 - 17962206

AN - SCOPUS:38849106118

VL - 19

SP - 353

EP - 358

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 2

ER -